Trial Profile
A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Biomarker; Therapeutic Use
- 21 Sep 2005 New trial record.